<?xml version="1.0" encoding="UTF-8"?>
<p>The global HCV prevalence is estimated at 2.5% (177.5 million of HCV-infected adults), ranging from 2.9% in Africa and 1.3% in the Americas [
 <xref rid="b119-ir-2019-09155" ref-type="bibr">119</xref>]. In the early 1990s, the prevalence of HCV was reported as 1.7% by enzyme immunoassay method among Korean individuals who underwent health screening program [
 <xref rid="b120-ir-2019-09155" ref-type="bibr">120</xref>]. More recently, a nationwide seroepidemiology study demonstrated that HCV antibody positivity rate in Korea was 0.78% [
 <xref rid="b121-ir-2019-09155" ref-type="bibr">121</xref>]. Additionally, HCV antibody positivity rate tended to increase with age. The rate was 0.34%, 0.41%, 0.60%, 0.80%, 1.53%, and 2.31% in individuals aged 20–29, 30–39, 40–49, 50–59, 60–69, and ≥ 70 years, respectively [
 <xref rid="b121-ir-2019-09155" ref-type="bibr">121</xref>]. A high-risk group for HCV infection includes individuals who inject drugs, patients who undergo dialysis, those with hemophilia or Hansen’s disease, and children born to HCV-positive mothers [
 <xref rid="b119-ir-2019-09155" ref-type="bibr">119</xref>,
 <xref rid="b122-ir-2019-09155" ref-type="bibr">122</xref>]. HCV is typically transmitted parenterally. Sexual, perinatal, and sporadic transmission are reported relatively infrequently [
 <xref rid="b2-ir-2019-09155" ref-type="bibr">2</xref>].
</p>
